9920 Belward Campus Drive
United States - Map
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The companys technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the companys VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
|Novavax, Inc.’s ISS Governance QuickScore as of Mar 1, 2014 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Stanley C. Erck ,
Chief Exec. Officer, Pres, Director and Member of Fin. Committee
|Mr. Russell P. Wilson J.D.,
Sr. VP of Bus. Devel.
|Dr. Gregory M. Glenn M.D.,
Sr. VP of R&D
|Dr. Timothy Jon Hahn Ph.D.,
Sr. VP of Manufacturing & Process Devel.
|Mr. Barclay A. Phillips ,
Chief Financial Officer, Sr. VP and Treasurer
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|